ALLY-2

Design Objective SVR 12 HCV RNA lt 25 IUml with 95 CI in treatmentnaïve genotyp e 1 treated for 12 weeks DCV SOF 400 mg QD DCV SOF 400 mg QD Randomisation 2 1 Openlabel

Embed this Presentation

Download Notice

Download Presentation The PPT/PDF document "ALLY-2" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.